SCHEMBL25259671

SCHEMBL25259671

Nc1nc2ccc(-c3ccc(N4CCOCC4)cc3)cc2s1

nearest known ligand 0.82

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.82
RAB9A P51151 3/20 0.82
SMN1; SMN2 Q16637 3/20 0.82
MAPT P10636 2/20 0.82
TP53 P04637 1/20 0.82
ALOX15 P16050 1/20 0.82
PIK3CA P42336 14/20 0.71
PI4KA P42356 10/20 0.58
PI4KB Q9UBF8 10/20 0.58
PIK3CD O00329 10/20 0.57
PIK3CB P42338 8/20 0.57
PIK3CG P48736 8/20 0.57
PIP5K1C O60331 4/20 0.57
APP P05067 1/20 0.55
GAA P10253 1/20 0.54
AR P10275 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31114781 1.00 NPC1 (0.82) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL74296 0.90 RAB9A (1.00) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL3711629 0.88 NPC1 (0.67) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL25834482 0.88 MAPT (0.63) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL28617302 0.83 PIK3CA (1.00) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL29970478 0.83 PIK3CA (1.00) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL12928473 0.82 PIK3CA (0.61) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL30450789 0.81 PIK3CA (0.58) NPC1RAB9ASMN1; SMN2MAPTTP53
SCHEMBL29646253 0.79 PIK3CA (0.82) RAB9AMAPTPIK3CAPI4KAPI4KB
SCHEMBL5532470 0.79 PIK3CA (0.82) RAB9AMAPTPIK3CAPI4KAPI4KB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INST NAT SANTE RECH MED (FR) 2025-12-18 US disclosed
EP-4460500-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) 2024-11-13 EP disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed
WO-2023131649-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 2023-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382273-A1 BENZOTHIAZOLE ANAOLOGUES AND USE THEREOF AS BOOSTERS OF ANTI TUBERCULOSIS DRUGS BBOX1, NDUFB6, NDUFB5 NPC1 3115/4885RAB9A 2727/4885SMN1; SMN2 4416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.